• Explore /
  • Poster
  • / A phase II study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma (nccRCC).

A phase II study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma (nccRCC).

Abstract Poster

Authors

Thomas Hutson

Thomas E. Hutson

Texas A&M HSC College of Medicine, Dallas, TX

Thomas E. Hutson , M Dror Michaelson , Timothy M. Kuzel , Neeraj Agarwal , Ana M. Molina , James J Hsieh , Ulka N. Vaishampayan , Sharon Xie , Urmi Bapat , Rohit K. Jain , Mayer N. Fishman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02915783

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 685)

Abstract #

685

Poster Bd #

G5

Abstract Disclosures

Similar Posters

First Author: E. Angevin

First Author: Andrew Johns

First Author: Chung-Han Lee

First Author: Do-Youn Oh